European Cannabis public-health surveillance

A dedicated evidence layer for population surveys, treatment records, sentinel hospitals, seizures, potency data, and policy tracking. These indicators describe public-health and market phenomena; they do not redefine the botanical identity of Cannabis sativa.

Kannabium home Return to Cannabis evidence Technology intelligence

EUROPEAN UNION DRUGS AGENCY · 2026

What these indicators measure, and what they do not

The European Union Drugs Agency combines population surveys, treatment records, sentinel hospitals, wastewater monitoring, seizures, potency data, and policy tracking. The measures are not interchangeable: each retains its own population, period, reporting system, and interpretive boundary.

Selected indicators from the European Drug Report 2026.
Indicator	Reported value	Scope	Interpretive boundary
Last-year use	8.7%; approximately 25 million people	European Union adults aged 15–64	Aggregate survey estimate. National survey years, age ranges, methods, and trends are heterogeneous.
Treatment demand	33% of reported demands; approximately 104,000 clients, including 62,000 first-time entrants	European Union, Norway, and Türkiye; 2024	Measures contact with specialist services, not population incidence. Coverage and referral pathways vary.
Hospital presentations	Median of 20% involving cannabis	Euro-DEN Plus sentinel hospitals; 2024	Sentinel-network indicator, not a population estimate. Cannabis was typically reported with other substances.
THC in seized material	Resin 24.6%; herbal cannabis 12%	European Union seizure data; 2024	Mean values for seized material. They do not represent all consumed products or a regulated commercial market.

Source: European Union Drugs Agency, European Drug Report 2026: Cannabis, updated 9 June 2026; DOI 10.2810/8266522.